Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals’ stock dipped 1.73%, underperforming the S&P 500’s mild loss, despite solid monthly gains. Investors ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.

Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes treatment trial.

Leerink Partners restated their market perform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) shares gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of intellectual property rights ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.